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INTRODUCTION 
During the 1960s and 1970s, the practice of 
pharmacywas evolving and emphasis was placed on 
patient safetyfactors as a result of patient injuries and 
deaths that hadoccurred because of problems with 
medication deliveryand sterile compounding. One of the 
first group‟s toaddress these patient safety issues was 
the NationalCoordinating Committee on Large Volume 
Parenteral (NCCLVP). NCCLVP was established by the 
US Pharmacopeia Convention, Inc., and subsequently 
developedand recommended standards of practice for 
the preparation, labeling, and quality assurance of 
hospital pharmacyadmixture services.
1–7
 
Parenteral medications are products which are 
introduced in a manner which circumvents the body‟s 
most protective barriers, the skin and mucous 
membranes, and, therefore, must be “essentially” free of 
biological contamination.  Most are injected or placed 
into the body tissues and do not pass thru the liver 
before entering the bloodstream. This can include 
injections, topical and inhalation routes. Generally in 
pharmacy, parenteral refers to injection and the topical 
and inhalation routes are separated into their own routes 
of administration. 
 Not all sterile dosage forms are administered by 
injection 
 Topical ophthalmic medication 
 Topical wound healing medications 
 Irrigation solutions 
Parenteral dosage forms differ from all other drug 
dosage forms, because they are injected directly into 
body tissue through the primaryprotective systems of 
the human body, the skin, and mucous membranes. 
They must be exceptionally pure and free from 
physical, chemical, and biological contaminants. These 
requirements place a heavy responsibility on the 
pharmaceutical industry to practice current good 
manufacturing practices (cGMPs) in the manufacture of 
parenteral dosage forms and on pharmacists and other 
health care professionals to practice good aseptic 
practices (GAPs) in dispensing parenteral dosage forms 
for administration to patients. Certain pharmaceutical 
agents, particularly peptides, proteins, and many 
chemotherapeutic agents, can only be given 
parenterally, because they are inactivated in the 
gastrointestinal tract when given by mouth. 
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ABSTRACT 
One of the first group‟s toaddress these patient safety issues was the NationalCoordinating Committee on Large Volume 
Parenteral (NCCLVP). Parenteral medications are products which are introduced in a manner which circumvents the body‟s 
most protective barriers, the skin and mucous membranes, and, therefore, must be “essentially” free of biological 
contamination.  Most are injected or placed into the body tissues and do not pass thru the liver before entering the bloodstream. 
This can include injections, topical and inhalation routes. Generally in pharmacy, parenteral refers to injection and the topical 
and inhalation routes are separated into their own routes of administration. NCCLVP was established by the US Pharmacopeia 
Convention, Inc., and subsequently developedand recommended standards of practice for the preparation, labeling, and quality 
assurance of hospital pharmacyadmixture services. Parenteral administration of drug is often critical and associated with 
problems such as limited number of acceptable excipients, stringent requirements of aseptic production process, safety issues, 
and patient noncompliance. Still this route maintains its value due to special advantages like quicker onset of action in case of 
emergency; target the drug quickly to desired site of action, prevention of first pass metabolism etc. This review 
highlightsformulation of parenteral product and advanced techniques involved in parenteral products. 
Keywords: NCCLVP, LVP, Aseptic area, GMP etc. 
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Parenterallyadministered drugs are relatively unstable 
and generally highly potent drugs that require strict 
control of administration to the patient. Due to the 
advent ofbiotechnology, parenteral products have 
grown in number and usage around the world. 
Parenteral preparations may require the use of 
excipients, for example; 
 To make the preparation isotonic with respect to 
blood 
 To adjust the pH, to increase solubility 
 To prevent deterioration of the active substances or 
 To provide adequate antimicrobial properties, but 
not to adversely affect the intendedmedicinal action 
of the preparation or, at the concentrations used, to 
cause toxicity or undue local irritation.  
Parenteral preparations are sterile preparations intended 
for administration by injection, infusion or implantation 
into the human or animal body
8
. The term “Parenteral” 
is applied to preparation administered by injection 
through one or more layers of skin tissue. The word is 
derived from the Greek words para and enteron, 
meaning outside of intestine and is used for dosage 
forms administered by routes other than the oral route. 
Parenteral preparations may require the use of 
excipients, for example to make the preparation isotonic 
with blood, to adjust the pH, to increase solubility, to 
prevent deterioration of the active substances or to 
provide adequate antimicrobial properties but not to 
adversely affect the intended medicinal action of the 
preparation or, at the concentrations used, to cause 
toxicity or undue local irritation. Examples of 
applications for prolonged release parenteral delivery 
include: fertility treatment, hormone therapy, protein 
therapy, infection treatments (antibiotics and 
antifungals), cancer therapy, orthopedic surgery and 
postoperative pain treatment, chronic pain treatment, 
vaccination/ immunization, treatment of CNS disorders, 
and immunosupression. Modified release (MR) 
parenteral drug products are available in several dosage 
forms, including microspheres, liposomes, gels, 
suspensions, in situ forming implants, lipophilic 
solutions, solid lipid nanoparticles (SLN) and drug 
eluting stents. 
 
Types of Sterile Products 
 
 
Parenteral therapy is used to:- 
 Produce a localized effect.  
 Administer drugs if the oral route cannot be used.  
 Deliver drugs to the unconscious patient.  
 Rapidly correct fluid and electrolyte imbalance. 
 Ensure delivery of the drug to the target tissues. 
Parenteral injections are either administered directly 
into blood for a fast and controlled effect or into tissues 
outside the blood vessels for a local or systemic effect.  
Parenteral products are sterile formulations that are 
administered into the body by various routes including 
injection, infusion and implantation. Injections are 
subdivided into small and large volume parenteral 
fluids. Small volumes parenteral are sterile, progen-free 
injectable products. They are packaged in volumes up to 
100 ml small volumes parenteral fluids are packed as: 
 Single dose ampoules.  
 Multiple- dose vials. 
 Prefilled syringes. 
Large volume parenteral products having a volume of 
100 ml or greater intended to be administered by 
intravenous routes are called as transfusion fluids or 
intravenous infusions. They are formulated as single 
dose injections that are administered by intravenous 
infusions. They are sterile aqueous solutions or 
emulsions with water for injections as the main 
component.  
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Large volume parenteral products include:- 
 Infusion fluids. 
 Total parenteral nutrition solutions.  
 Intravenous antibiotics.  
 Patient-controlled analgesia.  
 Dialysis fluids.  
 Irrigation solutions.  
Large volumes parenteral are variously formulated and 
packaged and have been used to:- 
 Restore fluid and electrolyte imbalance in patients 
suffering from dehydration, shock or injury. 
 Provide nutrition in circumstances were patients are 
malnourished e.g. total parenteral nutrition. 
 Act as a vehicle for administration of medicines. 
 Perform dialysis.  
 Allow irrigation of body parts. 
While water for injection is the main component of 
these products they also incorporate other ingredients 
including:-  
 Carbohydrates, e.g. dextrose, Sucrose and dextran 
 Amino acids 
 Lipid emulsions which contain vegetable or semi-
synthetic oil 
 Electrolytes such as sodium chloride 
 Polyols including glycerol, Sorbitol and mannitol 
Characteristics of sterile dosage forms:- 
 Sterility 
 Freedom from particulate matter 
 Freedom from pyrogens 
 Stability 
 Isotonicity
 
Route of Drug Administration:
9
 
 
 
FORMULATION OF PARENTERAL PRODUCTS 
Formulation Principal:-   
Parenteral drug are formulated as solution, suspension, 
emulsion, liposomes, microspheres, powder &nano-
system to be reconstituted as solution. These are 
commonly used in parenteral formulation focusing an 
solution & freeze dried products. 
Vehicles:- 
Water: The vehicle of greatest importance for 
parenteral product is water is suitable quality for 
compounding & rinsing product contact surfaces may 
be prepared either by distillation or by reverse osmosis, 
to meet united status pharmacopoeia specification of 
WFI  
Example: Sterile water injection. Water For injection 
Water miscible Vehicles: A number of solvent that are 
miscible with water have been used as a portion of a 
vehicle in the formulation of parenteral. These solvents 
are used primarily to solubilize certain drugs in aqueous 
vehicle & to reduce hydrolysis. 
Example: Ethyl Alcohol liquid polyethylene glycol , 
propylene glycol. 
Ethyl alcohol is used particularly in the preparation of 
solution of certain in Glycosides, Alkaloids, and then 
this prepare usually giving I.M. 
Non- aqueous vehicles: 
Fixed oils is a important group of non aqueous vehicle. 
The USP provides specification for such vehicle that the 
fixed oil must be vegetable origin so, that they will be 
the easily metabolized. Fixed oil is used particulars as a 
vehicle for certain hormones. 
The oils most commonly used are pea nut oil, sesame, 
cotton seed oil, olive oil, glycerin. Etc. 
Solutes:- 
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 Added  Substances :-  
The USP includes in this category all substances added 
a prento improve or safe-guard it‟s quality. An added 
substance may; 
1) Antimicrobial Agents :- 
The USP states that antimicrobial agents in 
bacteriostatic or fungistatic conn must be added to a 
prencontained in multiple close container. The USP 
provides the test for antimicrobial preservative 
effectiveness to determine that an antimicrobial 
substance because antimicrobial may have inherent 
toxicity for patient & USP prescribe the maximum 
value & connlimits they are used in parenteral products. 
Example:-Benzalkoniamchloride :– 0.001%., Cresol :- 
0.5%., Chlarobutanol :- 0.5%., Benzyl alcohol :-  1%. 
2) Buffers :- 
The use of buffering agents to maintain the PH of the 
parenteral product during it‟s storage is important for 
preventing the degradation, by ionization or by 
interaction of product with the material of the container. 
Buffer components are known to catalyze degradation 
of drugs, the acid salts most frequently as buffer. 
Example: - Citrates, phosphates, acetates, sodium, 
potassium, calcium & magnesium. 
3) Antioxidants :- 
Antioxidants are added, to prevent the oxidative 
degradation of the parenteral product. Ascorbic acid 
&it‟s salts are good antioxidants. 
Example:- Sodium bisalphite & other sulfurous acid 
salts. 
- Sodium formaldehyde sulfaxylate, 
- Thiourea, Acetone 
- Sodium metabisalphite. 
- EDTA. 
4) Tonicity:- 
They are used in parenteral& ophthalmic products to 
adjust the tonicity of the solution. The product 
areadministered to eye & spinal fluid must be isotonic; 
Injection in subcutaneous tissue and muscle should 
isotonic to minimize pain& tissue irritation. 
Example:-Electrolytes, Monosaccharide, Disaccharides, 
Sodium chloride 
5) Cryoprotectants & Lyoprotectants:- 
These are additives that serve to protect 
biopharmaceuticals from adverse effect due to freezing 
& drying of the product during freeze dry processes. 
Example:-  
Sugar such as sucrose, Trehalase, 
Amino acid such as – glycine, lysine. 
Polymers such as – liquid polyethylene glycol, dextran. 
Polyols such as mannitol, Sorbitol 
FORMULATION  
Suspensions
11-19 
Very difficult to formulate and produce Excellent 
stability: ships without caking/settling, Critical 
rheological properties: syringe ability: from container to 
syringe, Injectability: from syringe to vein. 
Components 
 Active ingredients 
 Aqueous vehicle 
 Surfactant for  wetting 
 Preservatives 
 Buffers 
Two basic methods: 
» Sterile vehicle & powder aseptic combination; 
» Sterile solutions are combined first and in situ 
crystallization. 
Emulsions 
Rarely used as parenteral products 
 Excellent stability requirement; 
 Particle size<1um, homodispersity; 
 Very limited selection of stabilizers & emulsifiers; 
1. w/o, allergy test, SB 
2. o/w, sustained-release, depot, IM 
3. o/w, nutrient emulsion, IV 
4. o/w type, use triglycerides as central core, 
phospholipid as   emulsifier, to provide essential 
fatty acids and calories 
Dry Powders 
Purpose:  To overcome the intrinsic instability of the 
drug, be reconstituted before use. 
Production Method 
 Freeze-drying 
 Aseptic crystallization and dry powder filling 
 Spray-drying 
Freeze-drying 
Advantages 
 Avoid damage to heat-sensitive drugs 
 High specific surface are facilitating complete 
rehydration 
 Improvement in filling accuracy 
Disadvantages: 
 Protective agents needed 
 Stability changing, crystalline/amorphous 
 High-cost and complicated 
1. Freeze-drying: Under low pressure, under the triple 
point of water, water was removed by sublimation.  
2. Sublimation : ice to vapor  directly 
3. Triple point of water : three phases coexisting in 
equilibrium 
TYPES OF PARENTERAL CONTROLLED DRUG 
DELIVERY SYSTEMS
20-25
:  
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Microspheres 
Microspheres designed for parenteral delivery, on the 
other hand, can be injected into the body using 
conventional needles and syringes. Thus, they have 
been the most widely accepted biodegradable polymer 
system for parenteral uses. However, the manufacturing 
processes for microspheres are often complex and 
difficult to control. As a result, there are often questions 
involving costs and batch-to-batch product uniformity 
4, 
5
.  
Liposomes 
Liposome‟s on the other hand are versatile carriers for 
both hydrophilic and lipophilic drug molecules but 
suffer from several disadvantages like, high production 
cost, leakage of drug, short half life and low solubility. 
6
 
Injectable gels 
Biodegradable injectable in situ gel forming drug 
delivery systems represent an attractive alternative to 
microspheres and implants as parenteral depot systems. 
It consists of biodegradable polymers dissolved in a 
biocompatible carrier. When the liquid polymer system 
is placed in the body using standard needles and 
syringes, it solidifies upon contact with aqueous body 
fluids to form solid implant. If a drug is incorporated 
into the polymer solution, it becomes entrapped within 
polymer matrix as it solidifies. Drug release occurs over 
time as polymer biodegrades. Biodegradable polymers 
used in these systems are Polyhydroxyacids, 
polyanhydrides, polyorthoesters, polyesteramides and 
others. Their importance will grow as numerous 
proteins will lose their patent protection in the near 
future
29-30
. 
Surgical implants 
Surgical implants can be made from biodegradable 
polymers using well-controlled manufacturing 
processes, such as extrusion, injection moulding, and 
compression moulding. These devices normally have 
very reproducible release profiles. However, because of 
their size, they require surgical implantation which 
often limits the product's market potential due to patient 
and physician acceptance issues.  
 
SUMMARY OF PARENTERAL 
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ADVANCED PARENTERAL DRUG DELIVERY 
SYSTEM
30-33
   
1) Liposomes  
Liposomes are formed by the self-assembly of 
phospholipid molecules in an aqueous  environment, the 
amphiphilic phospholipid molecules form a closed 
bilayer sphere in an attempt to shield their hydrophobic 
groups from the aqueous environment while still 
maintaining contact with the aqueous phase via the 
hydrophilic head group. The resulting closed sphere 
may encapsulate aqueous soluble drugs within the 
central aqueous compartment or lipid soluble drugs 
within the bilayer membrane. Alternatively, lipid 
soluble drugs may be complexed with cyclodextrins and 
subsequently encapsulated within the liposome aqueous 
compartment. The encapsulation of drugs with 
liposomes alters drug pharmacokinetics and this may be 
exploited to achieve targeted therapies. Alteration of the 
liposome surface is necessary in order to optimize 
liposomal drug targeting and to achieve prolonged 
circulation times liposome size between 70-200nm is 
necessary. Liposomes are the most widely studied 
modern drug delivery system because of its amazing 
application for the management of following diseases:  
 i) Liposomal anticancer agent -  
The use of liposomes as anticancer drug delivery 
systems was originally hampered by the realization that 
liposomes are rapidly cleared from the circulation and 
largely taken up by the liver macrophage. It was 
observed that doxorubicin loaded stealth liposomes 
circulate for prolonged periods, accumulate and 
extravagate within tumours & also improve tumoricidal 
activity. In one study it has been reported that in 
patients, liposomal doxorubicin accumulates within 
Kaposi„s sarcoma lesions and produces a good 
therapeutic response. Liposomal doxorubicin is now 
licensed as Caelyx, for the treatment of Kaposi„s 
sarcoma. This formulation is currently in clinical trials 
for ovarian cancer and could be approved shortly for 
use in ovarian cancer patients who have failed to 
respond to paclitaxel and cisplatin.   
ii) Liposomes as vaccine adjuvants -  
Liposomal vaccines can be made by associating 
microbes, soluble antigens, cytokines or 
deoxyribonucleic acid (DNA) with liposomes, the latter 
stimulating an immune response on expression of the 
antigenic protein. Liposomes encapsulating antigens, 
which are subsequently, encapsulated within alginate 
lysine microcapsules to control the antigen release and 
to improve the antibody response. Liposomal vaccines 
may also be stored dried at refrigeration temperatures 
for up to 12 months and still retain their adjuvanticity.  
 iii) Liposomal anti-infective agents -  
Liposomal amphotericin B (Ambisome), used for the 
treatment of systemic fungal infection. This is the first 
licensed liposomal preparation. It was observed in one 
study that liposomal amphotericin B, by passively 
targeting the liver and spleen, reduces the renal and 
general toxicity of the drug at normal doses.   
2) Niosomes:  
Niosomes are unilamellar or multilamellar vesicles, 
where in an aqueous solution is enclosed in highly 
ordered bilayer made up of nonionic surfactants with or 
without cholesterol (chol) and dicetyl phosphate and 
exhibit a behavior similar to liposomes in-vivo .They 
can be used in the treatment of cancer and also used as 
vaccine adjuvant. Some of its applications are:   
i) Anticancer niosomes -  
Anticancer niosomes, if suitably designed will be 
expected to accumulate within  tumours.  For example 
niosomal encapsulation of methotrexate and 
doxorubicin increases drug delivery to the tumour and 
tumoricidal activity. doxorubicinNiosomes having size 
200nm with a polyoxyethylene (molecular weight 
1,000) surface are rapidly taken up by the liver and 
accumulate to a lesser extent in tumour, this technology 
may prove advantageous for the treatment of hepatic 
neoplasms. It was also observed that the activity of 
other anticancer drugs, such as vincristine, bleomycin, 
plumbagin and a plant derived anticancer agent are 
improved on niosomal encapsulation.  
 ii) Niosomes at targeted site-  
Uptake by the liver and spleen make niosomes ideal for 
targeting diseases manifesting in these organs. One such 
condition is leishmaniasis and a number of other studies 
has shown that niosomal formulations of sodium 
stibogluconate improve parasite suppression in the liver 
spleen and bone marrow. Niosomes may also be used as 
depot systems for short acting peptide drugs on 
intramuscular administration.  
iii) Niosomes as vaccine adjuvant–  
It was studied that niosomal antigens are potent 
stimulators of the cellular and humoral immune 
response. The formulation of antigens as a niosome in 
water-in-oil emulsion further increases the activity of 
antigens and hence enhanced the immunological 
response.  
 3) Nanoparticles and Microparticles:  
Nanoparticles and microparticles are usually prepared 
by the controlled precipitation of polymers solubilised 
in one of the phases of an emulsion. Precipitation of the 
polymer out of the solvent takes place on solvent 
evaporation, leaving particles of the polymer suspended 
in the residual solvent. For particulate dispersions, the 
required particle size of nanoparticles lies between the 
range of 30-500nm while for microparticles in excess of 
0.5micron. Their applications in management of 
diseases are:  
 i) Tumor targeting Nanoparticles and microparticles-  
The accumulation of non-stealth doxorubicin 
nanoparticles within the Kupffer cells of the liver may 
be used to target hepatic neoplasms indirectly; this is 
achieved by providing a depot of drug for killing nearby 
neoplastic tissue. Microparticlesmay also be injected 
directly into tumours. It was observed that the direct 
injection of microparticles into solid tumours increases 
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the tumoricidal activity of the drugs 5- fluorouracil and 
doxorubicin.  
ii) Vaccine adjuvant-  
Nanoparticles have also been used as vaccine adjuvants. 
It was reported that antigens, which adsorbed onto the 
surface or entrapped in the matrix of 
polymethylmethacrylatenanoparticles induces an 
enhanced immunological response. For example 
polymethylmethacrylate Nanoparticles containing the 
influenza antigen may protect people against disease to 
a greater extent than the antigen alone.  
 iii) Other applications-  
Restenosis, defined as the re-obstruction of an artery 
following procedures such as angioplasty or 
artherectomy may be treated by the local application of 
dexamethasone-loaded polylactic acid co-glycolic acid 
nanoparticles. Cyclosporin A, an immunosuppressant 
drug used to prevent graft rejection after transplantation 
by the inhibition of T-lymphocytes, may be targeted to 
regional lymph nodes by the intramuscular 
administration of cyclosporin A polylactic acid 
nanoparticles. In short it can be said that, by virtue of 
their small size solid nanoparticles provide 
opportunities for targeted parenteral therapies and may 
also be used as immunoadjuvants.   
 4) Prodrugs -  
A prodrug is a pharmacological substance, which is 
administered in an inactive form. Once administered, it 
is metabolized in the body in vivo into the active 
compound. The use of prodrugs in cancer chemotherapy 
as a means of targeting relatively toxic compounds to 
specific areas of pathology is enjoying renewed activity. 
Two of the technologies being evaluated at present are 
antibody directed enzyme prodrug therapy (ADEPT) 
and the use of polymeric prodrug.  
 i) ADEPT  
an antibody-enzyme conjugate is administered 
intravenously, localizes in tumour tissue and 
subsequently activates an administered prodrug 
predominantly within such tumours. Prodrug activating 
enzyme is carboxypeptidase G2.  
 ii) Polymeric prodrugs -  
This involves the use of an active substance and 
possibly a targeting moiety, both linked viam spacers to 
a water-soluble polymeric backbone. From this basic 
blueprint a number of polymer drug conjugates used for 
cancer chemotherapy and have been synthesized with 
cleavable drug polymer linkers. These include soluble 
polymeric prodrugs of daunorubicin, doxorubicin, 
cisplatin and 5-fluorouracil. Passive tumour targeting 
with polymer drug conjugates improves the tumoricidal 
activity of anticancer agents. Distribution to potential 
sites of toxicity, such as the distribution of doxorubicin 
to heart tissue, is also decreased with polymer drug 
conjugates. In short, polymer drug conjugates have 
progressed from an elegant scientific concept to the 
clinic and may result in a new form of therapeutics for 
routine use. 
FUTURE SCOPE  
Many pharmaceutical manufacturers coming forward to 
formulate parenteral dosage form due to its beneficial 
characteristics over other conventional dosage 
forms.The dry-filling process also is much more cost 
effective because it requires less infra-structure as well 
as a reduced amount of energy and a shorter amount of 
time to produce a batch.  
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